Last reviewed · How we verify
in vitro sensitivity-directed chemotherapy
In vitro sensitivity-directed chemotherapy selects chemotherapeutic agents based on the sensitivity of tumor cells tested in a laboratory setting.
In vitro sensitivity-directed chemotherapy selects chemotherapeutic agents based on the sensitivity of tumor cells tested in a laboratory setting. Used for Pediatric solid tumors, including sarcomas and neuroblastoma.
At a glance
| Generic name | in vitro sensitivity-directed chemotherapy |
|---|---|
| Sponsor | Children's Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach involves testing various chemotherapeutic drugs against a patient's tumor cells in vitro to determine which drugs are most effective at killing the cancer cells. The results guide the selection of the most appropriate chemotherapy regimen for the patient.
Approved indications
- Pediatric solid tumors, including sarcomas and neuroblastoma
Common side effects
- Nausea and vomiting
- Bone marrow suppression
- Infection
Key clinical trials
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer (PHASE3)
- Cell Samples From Patients With Leukemia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: